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ABSTRACT 
Purpose. The fabrication of a ready-to-use immediate release tablets via 3D printing 
provides a powerful tool to on-demand individualization of dosage form. This work 
aims to adapt a widely used pharmaceutical grade polymer, polyvinylpyrrolidone 
(PVP), for instant on-demand production of immediate release tablets via FDM 3D 
printing. 
Methods. Dipyridamole or theophylline loaded filaments were produced via 
processing a physical mixture of API (10%) and PVP in the presence of plasticizer 
through hot-melt extrusion (HME). Computer software was utilized to design a caplet-
shaped tablet. The surface morphology of the printed tablet was assessed using 
scanning electron microscopy (SEM). The physical form of drug and its integrity 
following an FDM 3D printing were assessed using x-ray powder diffractometry 
(XRPD), thermal analysis and HPLC. In vitro drug release studies for all 3D printed 
tablets were conducted in a USP II dissolution apparatus. 
Results. Bridging 3D printing process with HME in the presence of a thermostable 
filler, talc, enabled the fabrication immediate release tablets at temperatures as low as 
110oC. The integrity of two models drugs was maintained following HME and FDM 3D 
printing. XRPD indicated that a portion of the loaded theophylline remained crystalline 
in the tablet. The fabricated tablets demonstrated excellent mechanical properties, 
acceptable in-batch variability and an immediate in vitro release pattern.  
Conclusions. Combining the advantages of PVP as an impeding polymer with FDM 
3D printing at low temperatures, this approach holds a potential in expanding the 
spectrum of drugs that could be used in FDM 3D printing for on demand manufacturing 
of individualised dosage forms.  
 
KEYWORDS: FDM; fused filament fabrication; HME; patient-specific; immediate 
release. 
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ABBREVIATIONS  
API  active pharmaceutical ingredient 
CAD   computer aided design 
DSC  differential scanning calorimetry 
FDM   Fused Deposition Modelling 
HME   hot melt extrusion 
HPLC  high performance liquid chromatography 
PLA  polylactic acid 
PVA  Poly(vinyl alcohol) 
PVP   polyvinylpyrrolidone 
SEM   scanning electron microscopy  
Tg   glass transition temperature 
Tm   melting point 
TGA   thermal gravimetric analysis 
XRPD  X-ray powder diffractometry 
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INTRODUCTION 
3D printing established roots in various disciplines from arts and engineering to 
implants and regenerative medicine (1, 2). As yet the exploitation of 3D printing for 
pharmaceutical applications is still at its infancy. However, with the emergence of the 
first FDA approved 3D printed tablet, Spritam (3), the momentum of this technology is 
on track to potentially change many means of production for oral dosage forms. 
The absence of large array of commercially available API combinations and 
strengths remains the most frequent problem facing compounding pharmacies today 
(4). Traditional tableting methods require multiple processing stages, costly facilities 
and experienced personnel, thus rendering tablet manufacturing impractical when 
dose modification for one or small group of patients is required. By contrast, 3D 
printing, not only circumvent these challenges of conventional tabletting, but also 
offers means of fabricating medicines at the point of dispensing (5). Amongst the 
different explored 3D printing technologies, fused deposition modelling (FDM) shows 
significant promise in low-cost dose fabrication (6). This stems up from the fact that 
FDM printers are available today at low cost and capable of producing 3D objects with 
a high accuracy and without post-printing steps (7).   
Fused deposition modelling (FDM) involves passing a filament based on thermoplastic 
polymersthrough a hot nozzle, where temperature is eleveted above its glass transition 
temperature (Tg) .The extruded material is deposited layer by layer to form an object, 
where solidification occurs in less than a second. The potential of FDM 3D printers 
has been explored in the incorporation of different API molecules through their loading 
into commercially available PVA filaments (7-9). These previous attempts, however, 
displayed several limitations such as the use of non-pharmaceutical grade ingredients 
and limited drug loading (9, 10). Previous reports suggested the need for using high 
temperatures [220 oC (8), 210 oC (9) and  250 oC (7)] when PVA based dosage forms 
were fabricated using FDM 3D printers. Moreover, several examples of PLA printed 
stuctures employed a temperature range of 180-210 oC (11-13).  
Despite the advancement in FDM 3D printing, the array of polymers currently exploited 
for FDM 3D printing remain limited. The employed polymers for FDM printing in oral 
drug delivery were restricted to the extended release polymers such as PVA (6-8) and 
PLA (14). The major limitation of FDM 3D printing renders it unsuitable for the 
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production of immediate release tablets, which count for approximately 70% of all oral 
dosage forms (15, 16). In rare example, our group reported the fabrication of 
immediate release tablet based on positively charged methacylic polymers (17). 
Polyvinylpyrrolidone (PVP) is known to have a growing pharmaceutical applications 
with solubility enhancing abilities (18-20). It is of great interest to adapt this water 
soluble polymer to fabricate tablet with immediate release profile. In this current work, 
we explored the feasibility of employing FDM 3D printing to encompass this important 
polymer in the pharmaceutical field. We have used temperature in this work, up to the 
authors knowledge, is the lowest to have been explored in constructing drug delivery 
dosage forms, hence broadening the spectra of materials that could be used with 
FDM.  
MATERIALS AND METHODS 
Materials 
Theophylline (melting point 270 oC) (21) was purchased from Acros Organics. 
Polyvinylpyrrolidone (PVP, MW 40,000) and dipyridamole (melting point 165 oC) (22) 
were purchased from Sigma-Aldrich (UK). Talc was ordered from Fluka Analytical 
(UK). Triethyl citrate was purchased from Sigma-Aldrich (Dorset,UK) and Scotch blue 
painter’s tape 50 mm was supplied by 3M (Bracknell, UK). 
Preparation of filaments using HME 
For the preparation of the API-free filaments a Thermo Scientific HAAKE MiniCTW hot 
melt extruder (Karlsruhe, Germany) was utilised. An optimised ratio of a powder 
mixture constituting of the polymer (PVP), plasticizer (TEC), filler (talc) and API 
(theophylline or dipyridamole) at (50,12.5, 27.5 and 10%wt) respectively, was 
gradually added to the HME and allowed to mix for 5 min at 100 oC to allow 
homogenous distribution of the molten mass. Afterwards, extrusion took place at 90 
oC at a torque of 0.4 Nm. 
Tablet design and printing 
Tablets in this study were designed in a caplet shape using an Autodesk® 3ds Max® 
Design 2012 software version 14.0 (Autodesk, Inc., USA). The templates design was 
then imported to the 3D printer’s software in a stereolithography (.stl) file format. For 
the printing of tablets, pre-prepared filaments were fed into a commercial FDM 3D 
6 
 
printer equipped with 1.75 mm nozzle size and MakerWare software Version 2.4.0.17 
(Makerbot Industries, LLC., USA). Tablets were printed using modified settings of the 
software as described earlier in our previous work (23). Tablets were printed using 
modified settings of the software as follows: type of printer: Replicator 2X; type of 
filament: PLA; resolution: standard; temperature of building plate: 40 °C; speed of 
extruder 90 mm/s while extruding and 150 mm/s while traveling; infill: 100%; height of 
the layer: 200 µm and nozzle temperature 110 °C. The design was printed without 
supports or raftsto avoid the need for post-printing finishing step. In order to improve 
caplet’s adhesion to the building plate, a blue Scotch Painter’s Tape was applied to 
the plate’s surface. 
 
Thermal analysis 
For modulated temperature differential scanning calorimetry (MTDSC) analysis, a 
differential scanning calorimeter (DSC) Q2000 (TA Instruments, Elstree, Hertfordshire, 
UK) with a heating rate of 2 °C/min was employed. Each sample was subjected to a 
heat-cool-heat scan in order to measure and exclude the effect of moisture contents 
on filament plasticity. A modulated scan was applied using an amplitude of 0.212 °C 
and a period of 40 sec was used, scanning from -70 to 200 °C. Analysis was carried 
out under a purge of nitrogen (50 mL/min). The data was analysed using a TA 2000 
analysis software. TA pin-holed lid and 40 µL aluminium pans and were filled with 
approximately 5 mg sample. All measurements were carried out in triplicates. 
For TGA analysis, printed tablets, raw materials as well as extruded filaments were 
measured using a TGA Q5000 (TA Instruments, Hertfordshire, UK). Samples (10 mg 
) were added to an aluminium pan without lid. Samples were then heated from 25  ̊C 
to 500 oC at a heating rate of 10 oC/min. All measurements were carried out in 
triplicates. 
X-ray Powder diffractometry (XPRD) 
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used 
to assess the physical form of APIs in PVP, PVP:TEC filament, API-free and API-
loaded filaments, and 3D printed tablets. Samples were scanned from 2Theta (2θ)= 
5° to 50° using 0.01° step width and a 1 second time count. The divergence slit was 1 
mm and the scatter slit 0.6 mm. The wavelength of the X-ray was 0.154 nm using Cu 
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source and a voltage of 30 kV. Filament emission was 10 mA using a scan type 
coupled with a two theta/theta scintillation counter over 30 min.  
Characterisation of the tablets properties 
Tablets in this study were characterised for; weight variation, drug content, friability, 
hardness and disintegration time. For determination of weight uniformity, 20 tablets 
were randomly selected and weighed individually using a digital analytical balance 
Ohaus® (Discovery DV215CD). The average weights of the tablets was measured and 
the percentage deviation from the mean was then determined. 
The crushing strength of 10 tablets was measured using a TBH 220 D (Erweka GmbH, 
Heusenstamm, Germany). The friability of the 3D printed tablets was determined using 
an Erweka Friability Tester TAR 10 (Erweka GmbH, Heusenstamm, Germany). 
Twenty tablets were randomly selected, weighed and tested at a rotation of 25 rpm for 
4 min. Tablets were then collected, dusted and reweighed.  The differences in weight 
were calculated and displayed as a percentage of the original sample weight. 
In order to determine the disintegration time for the 3D printed tablets, an Erweka ZT 
220 Disintegration tester (Erweka GmbH, Heusenstamm, Germany) was utilised. Six 
tablets were randomly selected and individually placed in the 6 cylinders of the basket 
rack assembly. The tablets in the cylinders were then covered with discs and the 
basket rack was immersed into a beaker containing 750 mL of 0.1 M HCl at 37±0.5 
oC. The time required for all tablets to leave the mesh was then visually assessed.  
Determination of drug content 
In order to examine the effect of HME and FDM 3D printing on the integrity of drug, 
API-loaded filaments and 3D printed tablets were analysed for drug content prior and 
following HME as well as in the 3D printed tablets. Samples (dipyridamole loaded 
filaments or tablets) were accurately weighed and placed in a 500 mL of 1:1 
water:acetonitrile mixture for 2 h under sonication. The solution were filtered through 
0.22 μm Millex-GP syringe filters (Merck Millipore, USA) and prepared for HPLC 
analysis.  
Dipyridamole contents in relevant samples were assessed using an Agilent UV-HPLC 
1260 series (Agilent Technologies, Inc., Germany) equipped with XTerra RP 18 
column (150 x 4.6 mm, 5µm particle size) (Waters, Ireland) at temperature 40oC. The 
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mobile phase (60:40 phosphate buffer pH 6.8: acetonitrile) was employed at a flow 
rate 1 mL/min and dipyridamole was detected at a wavelength of 282 nm.  The 
injection volume was10 µL and a stop time was 10 min per sample.  
For theophylline, the same UV-HPLC system and column were used as detailed 
above. A mobile phase constituted of 10 mM solution of ammonium acetate buffer, 
methanol and acetonitrile (86:7:7) was used. Analysis was carried out at a wavelength 
of 272 nm, temperature of 40 oC, flow rate of 1 ml/min, injection volume was 5 µL and 
a run time of 7 min. 
Scanning electron microscopy (SEM) 
The surface morphology of the filaments and the printed tablets was examined using 
Quanta-200 SEM microscope at 20 kV. Samples were placed on a metallic stub and 
gold coated under vacuum using JFC-1200 Fine Coater (Jeol, Tokyo, Japan). 
Photographs of the tablets were also taken with a Canon EOS-1D Mark IV (Canon 
Ltd, Japan). 
In vitro drug release studies 
In vitro drug release studies was investigated using an Erweka DT 600 dissolution 
tester (USP II). Three tablets were randomly selected and individually placed in the 
dissolution vessels each containing 900 mL of 0.1M HCL and stirred at 50 rpm and 
37±0.5 oC. Four mL aliquots were manually collected using 5 mL Leur-Lok syringes at 
(0,5,10,15,20,25,30,40,50,60 and 70 min) time intervals and filtered through a Millex-
HA 0.45-µm filter. Each aliquot withdrawn was replaced with 4 mL of 0.1M HCl. The 
absorbance of the samples were finally measured using a UV spectrophotometer 
(Bibby Scientific Ltd, UK) at 282 and 272 nm for dipyridamole and theophylline 
respectively.  
Statistical analysis 
One-way ANOVA was employed using SPSS Software (22.0.0.2) to analyse the 
results. Differences in results above probability level (p > 0.05) was considered not 
significant whilst; (p<0.001) were considered very significant and between p = 0.01 
and 0.05 were considered significant. 
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RESULTS AND DISCUSSION 
Fig. 1 illustrates different step used in the preparation of tablets by combining HME 
and FDM 3D printing. API, polymer and other filler were physically mixed and 
processed via HME to produce 1.75 mm filament at 90 oC. CAD software was used to 
produce a capsule-shaped tablet that was printed via a benchtop FDM 3D printer.  
PVP is frequently used in HME to enhance the dissolution pattern of poorly soluble 
molecules (24-28). TGA thermographs (Figs. 2A-B) revealed a significant mass loss 
of PVP filaments around 100 oC due to dehydration of the PVP filaments. A second 
mass loss was also apparent at 400 oC indicating the degradation of PVP. Also the 
plasticiser TEC degrades at temperatures >200 oC (Figs. 2A-B). This renders it 
unsuitable for FDM 3D printing under the recommended printing temperature of 200-
220 oC, thus highlighting the importance of lowering the temperature during the 
process of 3D printing to suit a variety of APIs and pharmaceutical excipients. The 
thermal stability of dipyridamole (29) and theophylline (30) were in agreement with 
previous reports and both APIs were stable at temperatures <200 oC.  
When PVP filament (no filler) were used as a feed for 3D printer, it was not possible 
to fabricate a structure via FDM 3D printing process due to poor flow from the hot 
nozzle of printer and the formation of collapsed structure (data not shown). In order to 
formulate a stable structure and allow rapid solidification of the filament from the hot 
nozzle of the 3D printer, a thermostable filler, talc (melting points being >1500 oC), 
was added to the composition of the filament. The latter did not degrade at the 
temperature range utilised in this study (31). 
DSC thermographs, at the first heat-scan, all displayed a large endothermal event in 
the range of 50-110 oC due to polymer dehydration (Fig. 3). This might be related to 
the hygroscopic nature of PVP, where electronegative groups of the carbonyl in 
pyrrolidone structure are able to from hydrogen bonds with water (32). Therefore, a 
modulated heat-scan was utilized to assess this event-complex. In order to assess the 
impact of water on glass transition temperature (Tg), a heat-cool-heat scan was 
employed.  
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The reversing heat flow of the first heat-scan indicated that the Tg of PVP filament 
(plasticised with TEC) to be in the range of 19-35 oC. This Tg is significantly lower than 
expected from Gordon-Taylor equation (Tg =82.3 oC) and is related to the plasticising 
effect of water. On the other hand, the second heat-scan indicated a significantly 
higher Tg value of 93 oC  (in comparison to the Tg of first heat-scan, p<0.05), 
confirming that moisture has an impact on the plasticity of PVP. Such a plasticizing 
effect of moisture on PVP was previously reported (33, 34).  
The addition of talc did not show any significant effect on the thermal behaviour of 
PVP as noted in the first and second heat-scans. The addition of dipyridamole and 
theophylline shifted the Tg of the filament in the second scan from 93 oC to 73 and 69 
oC respectively. Such depression in the Tg indicates a plasticizing effect of 
dipyridamole and theophylline. Similar findings have been reported earlier for other 
API-PVP blends (35).  
The XRPD patterns of dipyridamole loaded filament and tablets (Fig.4) showed the 
absence of peaks at (2θ)= 10.13, 17.89, 18.91, 20.42, 20.98, 23.65, 26.12, 28.49, 
30.45o (36), indicating no crystalline presence in the PVP matrices . XRPD spectra for 
theophylline alone elucidated diffraction peaks at (2θ) =7, 12, 14 and 24° analogous 
to previous findings (23, 37). However, the presence of some peaks at (2θ) =12 and 
7° indicated that a percentage of theophylline remained in the crystalline form.  
In order to examine the effect of hot melt extrusion and 3D printing on the APIs, drug 
content analysis in the HME extruded filaments prior to 3D printing as well as in the 
3D printed tablets was carried out. As elucidated in Fig. 5B, the content of drug was 
neither affected by HME extrusion nor by 3D printing. Content uniformity was found to 
be 102.60 ±0.59% and 100.23 ±0.09% for dipyridamole and theophylline, respectively, 
in the extruded filaments. This high drug content was found to remain the same in the 
3D printed tablets (101.18 ±3.91% and 99.56 ±0.48%) for dipyridamole and 
theophylline, respectively. In an earlier study, FDM 3D printing at (210 °C) was found 
to  thermally degrade more than half the drug load (5-ASA) (38). Lowering the printing 
temperature to 110 °C against the recommended temperature by the 3D printer 
manufacturer (230°C)(39) favours its use for various materials, as reflected by the high 
drug content in this study.  
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Photographs and SEM images showed that the structure of filament was smooth with 
few apparent gaps or voids (Figs. 1E and 5A). Fabricated tablets were constructed 
from overlaid layers of filament with an approximate height of 200 μm. This thickness 
can be increased to 400 µm or decreased into 100 µm per layer, as required, via 
adjusting the resolution of the slicing engine  of the printer (23). The potential of 
utilising FDM 3D printing in modifying the dose to suit patient’s individual needs by 
controlling the volume of the printed drug delivery system has also been demonstrated 
(7, 23).  
The 3D printed tablets were evaluated for weight variation, dimensions, hardness and 
friability (Table I).  The friability was reported to be 0% for all the formulation and the 
crushing strength required to deform or break the tablets was high >350 N. These 
values clearly demonstrates the superiority of FDM 3D printing over other 3D printed 
technologies such as extrusion-based (40) and powder-based 3D printing (41, 42) in 
terms of producing mechanically strong tablets. The generation of ready-to-use tablets 
at the end of the printing process without any need for finishing or drying step is 
another instrumental advantage of FDM 3D printing where individualised dosage 
forms are instantly fabricated on demand.  
The disintegration time of 3D printed tablets was found to be <15 min for all tested 
tablets (Table I). The applicability of utilising the polymer PVP as an immediate release 
polymer was also demonstrated through the in vitro dissolution of the drugs from the 
3D printed tablets. As elucidated in dissolution data (Fig. 5c), more than 85% of 
dipyridamole and theophylline were released within the first 30 min. This confirms the 
suitability of PVP as a hydrophilic carrier for engineering immediate release 3D printed 
dosage forms (43).  
In summary, by lowering the temperature of FDM 3D printing process using a 
hydrophilic polymer, this work reveals the potential of adapting this 3D printing 
technology to a wider spectrum of drug molecules and to commonly used immediate 
release dosage forms. Here, the filament-forming process is HME. However, there are 
a series of other kinds of filament-forming methods such as wet spinning, dry spinning 
and electrospinning. (44, 45) This work also provides a concept about the combined 
usage of advanced technologies for creating novel solid dosage forms. 
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CONCLUSION 
By combing FDM with HME, it was possible to fabricate 3D printed tablets with 
immediate release properties based on PVP and talc as a matrix former and a 
thermostable filler. The tablets were suitable to make two model drugs and achieved 
immediate release properties. Tablets showed excellent mechanical properties and 
acceptable in-batch variability. To the authors’ knowledge, this is the first report of 
employing PVP in FDM 3D printing and a rare example of employing the process to 
produce immediate release tablets. The reported approach can be employed to 
fabricate patient-tailored tablets at relatively lower temperature (110 oC) and using 
pharmaceutically approved and solubility enhancing polymer. This work confirms the 
possibility of expanding the use of FDM 3D printing to a wider range of temperatures 
for on-demand fabrication of immediate release products. 
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Table I Weight uniformity, API contents, friability, crushing strength, disintegration time and 
dimensions of PVP based tablets (n=3 ±STD). 
Drug Weight 
Uniformity 
±SD (mg) 
Drug 
content 
±SD (%) 
Friability 
 (%) 
Crushing 
strength 
(N) 
Disintegration 
time (min) 
Tablet Dimensions 
(Length X Width X Height) 
L ±SD 
(mm) 
W ±SD 
(mm) 
H±SD 
(mm) 
Dipyridamole 121.68 ± 
9.28 
 
101.18 ± 
3.91 
 
 
0 432.67 10 9.23 
±0.15 
3.86 
±0.09 
3.80 
±0.12 
Theophylline 111.01 ± 
5.30 
99.56 
±0.48 
 
0 379.00 13 9.43 
±0.07 
3.65 
±0.02 
3.54 
±0.08 
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Fig. 1 Schematic illustration of the fabrication of Immediate release 3D-printed tablet. (A) 
Materials mixture (API, PVP and talc) are processed through HME to produce (B) API loaded 
PVP filament ( is extruded (C) Stereolithographic file is designed via CAD software and (D) 
FDM 3D printer uses the filament as a feed to fabricate drug loaded immediate release tablet 
(E) at 110 oC. 
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Fig. 2 TGA Thermal degradation profiles of TEC, PVP, PVP:TEC filament, API-free and API 
loaded filaments, and 3D printed tablets for (A) theophylline and (B) dipyridamole. 
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Fig. 3 Reversing DSC thermographs of PVP, PVP:TEC filament, API-free and API-loaded 
filaments, and 3D printed tablets for dipyridamole (A1 First heat-scan and A2 second heat-
scan) and theophylline (B1 First heat-scan and B2 second heat-scan). 
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Fig. 4 XRPD patterns of PVP, PVP:TEC filament, API-free and API-loaded filaments, and 3D 
printed tablets for theophylline (A) and dipyridamole (B). 
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Fig. 5 (A ) Photographs of 3D printed API-loaded tablets, (B) Durg contents before and after 
HME process and following FDM 3D printing, (C) In vitro dissolution profile  of theophylline 
and dipyridamole from PVP based 3D printed tablets using USPII dissolution apparatus. 
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